IM-18

N/A

Report date: 2023/12/14 15:03:29

Base Information

Drug NameIM-18

Drug Alias NameIM-18IM18

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements

TargetsUpdating

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesImunopharm Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesImunopharm Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsMelanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A